Role of vitamin D 3 in arterial blood pressure control;Rola witaminy D 3 w patogenezie nadciśnienia tetniczego

Polski Merkuriusz Lekarski

Volumn 23, Issue 136, 2007, Pages 307-310

  Bednarski, Rafał ^a,b   Donderski, Rafał ^a   Manitius, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Katedra I Klinika Nefrologii   (Poland)

Author keywords

Arterial hypertension; Cardiovascular disease; Vitamin D 3

Indexed keywords

CALCIUM; COLECALCIFEROL; PHOSPHORUS;

BLOOD; BLOOD PRESSURE; HUMAN; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

BLOOD PRESSURE; CALCIUM; CHOLECALCIFEROL; HUMANS; HYPERTENSION; PHOSPHORUS; RENIN-ANGIOTENSIN SYSTEM;

EID: 35948970592     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Agarwal R., Acharya M., Tian J. i wsp.: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int., 2005, 68, 2823-2828.
2. 3. Biochemistry, 1968, 7, 3317-3322.
3. Brickmann A.S., Nyby M.D., von Hungen K. i wsp.: Calcitropic Hormones, platelet calcium and blood pressure in essential hypertension. Hypertension, 1990, 16, 515-522.
4. Dusso A.S., Brown A.J., Slatopolsky E.: Vitamin D. Am. J. Physiol. Renal Physiol., 2005, 289, 8-28.
5. Forman J.P., Bischoft-Ferrari H.A., Willett W.C. i wsp.: Vitamin D intake and risk of incident hypertension. Results from three large prospective cohort studies. Hypertension, 2005, 46, 676-682.
6. 3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 2001, 98, 6800-6805.
7. Holick M.F.: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers and cardiovascular disease. Am. J. Clin. Nutr., 2004, 80, suppl. 6, 1678-1688.
8. Hypponen E., Laara E., Reunanen A. i wsp.: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet, 2001, 358, 1500-1503.
9. Jorde R., Svartberg J., Sundsfjord J.: Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J. Hypertens., 2005, 23, 1639-1644.
10. Jorde R., Sundsfjord J., Haug E. i wsp.: Relation between low calcium intake, parathyroid hormone, and blood pressure. Hypertension, 2000, 35, 1154-1159.
11. Krause R., Bühring M., Hopfenmüller W. i wsp.: Ultraviolet B and blood pressure. Lancet, 1998, 352, 709-710.
12. Kristal-Boneh E., Froom P., Harari G. i wsp.: Association of calcitriol and blood pressure in normotensive men. Hypertension, 1997, 30, 1289-1294.
13. Levin A., Li Y.: Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney diseases? Kidney Int., 2005, 68, 1973-1981.
14. 3 is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest., 2002, 110, 229-238.
15. Lind L., Pollare T., Hvarfner A. i wsp.: Long-term treatment with active vitamin D (alphacalcidiol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res., 1989, 11, 141-147.
16. Lind L., Wengle B., Wide L. i wsp.: Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma renin activity and calcium status. A double-blind, placebo-controlled study. Am. J. Hypertens., 1989, 2, 1, 20-25.
17. Mac Carthy E.P., Yamashita W., Hsu A. i wsp.: 1,25-dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension, 1989, 13, 954-959.
18. Mathieu C., Adorini L.: The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med., 2002, 8, 174-179.
19. Mc Carron D.A., Pingree P.A., Rubin R.J. i wsp.: Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension, 1980, 2, 162-168.
20. Mellanby E.: An experimental investigation on rickets. Lancet, 1919, 1, 407-412.
21. Nyirenda M.J., Padfield P.L: Parathyroid hormone and hypertension. J. Hypertens., 2005, 23, 1633-1634.
22. Pfeifer M., Begerow B., Minne H.W. i wsp.: Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J. Clin. Endocrinol. Metab., 2001, 86, 1633-1637.
23. Resnick L.M., Muller F.B., Laragh J.H.: Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann. Intern. Med., 1986, 105, 649-654.
24. 3. Hypertension, 1993, 21, 253-258.
25. Shoback D., Marcus R., Bikle D., i wsp.: Metabolizm składnikow mineralnych i choroby metaboliczne kosci (red. Andrzej Lewinski). Wydawnictwo Czelej. Wydanie. Lublin, 2004, 296-362.
26. Strazzullo P., Nunziata V., Cirillo M. i wsp.: Abnormalities of calcium metabolism in essential hypertension. Clin. Sci., 1983, 65, 137-141.
27. Szczepańska-Sadowska E.: Układ renina-angiotensyna - fizjologia i patofizjologia W: Antagonisci receptora angiotensyny Il w leczeniu chorób układu sercowo-naczyniowego, (red. Januszewicz A., Januszewicz W., Ruzyłło W.), Medycyna Praktyczna. Krakow, 2006, 21-56.
28. Teng M., Wolf M., Ofsthun M.N. i wsp.: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol., 2005, 16, 1115-1125.
29. Tillman D.M., Semple P.F.: Calcium and magnesium in essential hypertension. Clin. Sci., 1988, 75, 395-402.
30. Timms P.M., Mannan N., Hitman G.A., iwsp.: Circulating MMP-9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM, 2002, 95, 787-796.
31. Tozawa M., Iseki K., Iseki C. i wsp.: Seasonal blood pressure and body weight variation in patients on chronic hemodialysis. Am. J. Nephrol., 1999, 19, 660-667.
32. Watson K.E., Abrolat M.L., Malone L.L. i wsp.: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation, 1997, 96, 1755-1760.